ArticleEClinicalMedicine2021

Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.

Sergey V Zhuravel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.